opinion @ First Albany weakens Anika Therapeutics Inc Says outlook uncertain
December - Analysts at First Albany maintain their "neutral" rating on Anika Therapeutics Incorporated (ANIK.NAS), while , the analysts mention that the company has received only $5 million as milestone payment from JNJ/OBI, while losing out on the remaining $7.5 million reimbursement-related payment. The analysts expect there to be lack of visibility into Anika Therapeutics' sales till mid-2205 and into the company's reimbursements till late next year. The EPS estimates for FY04 and FY05 have been reduced from $0.25 to $0.24 and from $0.26 to $0.22, respectively. reducing their estimates for the company. The 12-month target price has been reduced from $11.40 to $10.00
---------
Market Data 
Markets 
AI
